Merck Announces Positive Phase 2b/3 Results for Clesrovimab in RSV Prevention Trial for Infants

Jul 23, 2024, 12:30 PM

Merck has announced positive topline results from its Phase 2b/3 trial of Clesrovimab (MK-1654), an investigational monoclonal antibody designed to prevent respiratory syncytial virus (RSV) in infants. The antibody-based drug met the main goal of reducing the incidence of lower respiratory infection compared to a placebo in a mid-to-late stage trial. The study, announced on Tuesday, also confirmed the safety profile of the treatment. Merck's announcement highlights the potential of Clesrovimab to protect infants from RSV-related diseases.